Please Wait.....
Report
APAC Acute LymphocyticLymphoblastic Leukemia (ALL) Diagnostics Market
Market Report I 2022-12-01 I 266 Pages I Data Bridge Market Research
The Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market is projected to register a substantial CAGR of 8.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030
Market Segmentation:
Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:
- Rise in preference for preventive health check-ups
- Increase in awareness about the leukemia cancer diagnostics
Market Players:
Some of the major players operating in the Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- QIAGEN
- Abbott
- Merck KGaA
- Siemens Medical Solutions USA, Inc.
- Hologic, Inc.
- Agilent Technologies, Inc.
- DiaSorin S.p.A.
- Illumina, Inc.
- Myriad Genetics, Inc.
- bioMerieux SA
- Quest Diagnostics Incorporated
- Bio-Rad Laboratories, Inc.
- Koninklijke Philips N.V.
- BD
- Exact Sciences Corporation
- Time Medical Holding
- PlexBio
- MinFound Medical Systems Co., Ltd
- Medonica Co. LTD
TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 57
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 MULTIVARIATE MODELLING 66
2.7 PRODUCT TYPE LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET TESTING TYPE COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72
3 EXECUTIVE SUMMARY 73
4 PREMIUM INSIGHTS 76
4.1 PESTEL ANALYSIS 77
4.2 PORTER'S FIVE FORCES 78
4.3 INDUSTRY INSIGHTS 79
5 EPIDEMIOLOGY 81
6 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 82
7 MARKET OVERVIEW 85
7.1 DRIVERS 87
7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 87
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 88
7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 88
7.2 RESTRAINTS 90
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 90
7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 91
7.3 OPPORTUNITIES 91
7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 91
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 92
7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 92
7.4 CHALLENGES 93
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94
8 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 95
8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
8.2.1 BIOPSY INSTRUMENTS 100
8.2.1.1 BONE MARROW BIOPSY 100
8.2.1.2 NEEDLE BIOPSY 100
8.2.1.3 SURGEON BIOPSY 101
8.2.1.4 OTHERS 101
8.2.2 PATHOLOGY-BASED INSTRUMENTS 101
8.2.2.1 PCR INSTRUMENTS 101
8.2.2.2 SLIDE STAINING SYSTEMS 101
8.2.2.3 TISSUE PROCESSING SYSTEMS 101
8.2.2.4 CELL PROCESSORS 102
8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 102
8.2.3 IMAGING INSTRUMENTS 102
8.2.3.1 ULTRASOUND SYSTEMS 102
8.2.3.2 CT SYSTEMS 102
8.2.3.3 MRI SYSTEMS 102
8.2.3.4 OTHERS 103
8.2.4 OTHERS 103
8.3 CONSUMABLES & ACCESSORIES 103
8.3.1 KITS 104
8.3.1.1 PCR KITS 104
8.3.1.2 DNA POLYMERASE KITS 104
8.3.1.3 NUCLEIC ACID ISOLATION KITS 104
8.3.1.4 OTHERS 105
8.3.2 REAGENTS 105
8.3.2.1 ASSAYS 105
8.3.2.2 BUFFERS 105
8.3.2.3 PRIMERS 105
8.3.2.4 OTHERS 105
8.3.3 PROBES 106
8.3.4 OTHER CONSUMABLES 106
9 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 107
9.1 OVERVIEW 108
9.2 BIOPSY 111
9.2.1 BONE MARROW BIOPSY 112
9.2.2 NEEDLE BIOPSY 112
9.2.3 SURGEON BIOPSY 112
9.2.4 OTHERS 112
9.3 BLOOD TEST 113
9.3.1 BLOOD CHEMISTRY TESTS 114
9.3.2 COMPLETE BLOOD COUNT (CBC) 114
9.3.3 OTHERS 114
9.4 IMAGING TEST 114
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 115
9.4.2 MRI 115
9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 116
9.4.4 OTHERS 116
9.5 OTHERS 116
10 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 117
10.1 OVERVIEW 118
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 121
10.2.1 EARLY PRE-B ALL 122
10.2.2 COMMON ALL 122
10.2.3 PRE-B ALL 122
10.2.4 MATURE B-CELL ALL 122
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 122
10.3.1 PRE-T ALL 123
10.3.2 MATURE T-CELL ALL 123
11 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 124
11.1 OVERVIEW 125
11.2 BELOW 21 128
11.3 21-29 129
11.4 30-65 130
11.5 65 AND ABOVE 131
12 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 132
12.1 OVERVIEW 133
12.2 MALE 136
12.3 FEMALE 137
13 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 138
13.1 OVERVIEW 139
13.2 HOSPITALS 142
13.3 ASSOCIATED LABS 142
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 143
13.5 DIAGNOSTIC IMAGING CENTERS 144
13.6 CANCER RESEARCH INSTITUTES 144
13.7 OTHERS 145
14 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 146
14.1 OVERVIEW 147
14.2 DIRECT TENDER 150
14.3 RETAIL SALES 151
15 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 152
15.1 ASIA-PACIFIC 153
15.1.1 CHINA 164
15.1.2 JAPAN 169
15.1.3 INDIA 174
15.1.4 AUSTRALIA 179
15.1.5 INDONESIA 184
15.1.6 SOUTH KOREA 189
15.1.7 VIETNAM 195
15.1.8 THAILAND 200
15.1.9 PHILIPPINES 205
15.1.10 MALAYSIA 210
15.1.11 SINGAPORE 215
15.1.12 REST OF ASIA PACIFIC 220
16 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 221
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 221
17 ASIA PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 222
17.1 F. HOFFMANN-LA ROCHE LTD. 222
17.1.1 COMPANY SNAPSHOT 222
17.1.2 REVENUE ANALYSIS 222
17.1.3 COMPANY SHARE ANALYSIS 223
17.1.4 PRODUCT PORTFOLIO 223
17.1.5 RECENT DEVELOPMENT 223
17.2 THERMO FISHER SCIENTIFIC INC. 224
17.2.1 COMPANY SNAPSHOT 224
17.2.2 REVENUE ANALYSIS 224
17.2.3 COMPANY SHARE ANALYSIS 225
17.2.4 PRODUCT PORTFOLIO 225
17.2.5 RECENT DEVELOPMENT 225
17.3 QIAGEN 226
17.3.1 COMPANY SNAPSHOT 226
17.3.2 REVENUE ANALYSIS 226
17.3.3 COMPANY SHARE ANALYSIS 227
17.3.4 PRODUCT PORTFOLIO 227
17.3.5 RECENT DEVELOPMENT 227
17.4 ABBOTT 228
17.4.1 COMPANY SNAPSHOT 228
17.4.2 REVENUE ANALYSIS 228
17.4.3 COMPANY SHARE ANALYSIS 229
17.4.4 PRODUCT PORTFOLIO 229
17.4.5 RECENT DEVELOPMENT 229
17.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 230
17.5.1 COMPANY SNAPSHOT 230
17.5.2 REVENUE ANALYSIS 230
17.5.3 COMPANY SHARE ANALYSIS 231
17.5.4 PRODUCT PORTFOLIO 231
17.5.5 RECENT DEVELOPMENT 231
17.6 MERCK KGAA 232
17.6.1 COMPANY SNAPSHOT 232
17.6.2 REVENUE ANALYSIS 232
17.6.3 PRODUCT PORTFOLIO 233
17.6.4 RECENT DEVELOPMENT 233
17.7 HOLOGIC INC. 234
17.7.1 COMPANY SNAPSHOT 234
17.7.2 REVENUE ANALYSIS 234
17.7.3 PRODUCT PORTFOLIO 235
17.7.4 RECENT DEVELOPMENT 235
17.8 AGILENT TECHNOLOGIES, INC. 236
17.8.1 COMPANY SNAPSHOT 236
17.8.2 REVENUE ANALYSIS 236
17.8.3 PRODUCT PORTFOLIO 237
17.8.4 RECENT DEVELOPMENT 237
17.9 BD 238
17.9.1 COMPANY SNAPSHOT 238
17.9.2 REVENUE ANALYSIS 238
17.9.3 PRODUCT PORTFOLIO 239
17.9.4 RECENT DEVELOPMENT 239
17.10 BIOMERIEUX SA 240
17.10.1 COMPANY SNAPSHOT 240
17.10.2 REVENUE ANALYSIS 240
17.10.3 PRODUCT PORTFOLIO 241
17.10.4 RECENT DEVELOPMENTS 241
17.11 BIO-RAD LABORATORIES, INC. 242
17.11.1 COMPANY SNAPSHOT 242
17.11.2 REVENUE ANALYSIS 242
17.11.3 PRODUCT PORTFOLIO 243
17.11.4 RECENT DEVELOPMENT 243
17.12 DIASORIN S.P.A. 244
17.12.1 COMPANY SNAPSHOT 244
17.12.2 REVENUE ANALYSIS 244
17.12.3 PRODUCT PORTFOLIO 245
17.12.4 RECENT DEVELOPMENTS 245
17.13 EXACT SCIENCE CORPORATION 246
17.13.1 COMPANY SNAPSHOT 246
17.13.2 REVENUE ANALYSIS 246
17.13.3 PRODUCT PORTFOLIO 247
17.13.4 RECENT DEVELOPMENT 247
17.14 ILLUMINA, INC. 248
17.14.1 COMPANY SNAPSHOT 248
17.14.2 REVENUE ANALYSIS 248
17.14.3 PRODUCT PORTFOLIO 249
17.14.4 RECENT DEVELOPMENT 249
17.15 KONINKLIJKE PHILIPS N.V. 250
17.15.1 COMPANY SNAPSHOT 250
17.15.2 REVENUE ANALYSIS 250
17.15.3 PRODUCT PORTFOLIO 251
17.15.4 RECENT DEVELOPMENT 251
17.16 MEDONICA CO. LTD 252
17.16.1 COMPANY SNAPSHOT 252
17.16.2 PRODUCT PORTFOLIO 252
17.16.3 RECENT DEVELOPMENT 252
17.17 MICHAEL DIAGNOSTICS LTD 253
17.17.1 COMPANY SNAPSHOT 253
17.17.2 PRODUCT PORTFOLIO 253
17.17.3 RECENT DEVELOPMENT 253
17.18 MINFOUND MEDICAL SYSTEMS CO., LTD 254
17.18.1 COMPANY SNAPSHOT 254
17.18.2 PRODUCT PORTFOLIO 254
17.18.3 RECENT DEVELOPMENT 254
17.19 MYRIAD GENETICS, INC. 255
17.19.1 COMPANY SNAPSHOT 255
17.19.2 REVENUE ANALYSIS 255
17.19.3 PRODUCT PORTFOLIO 256
17.19.4 RECENT DEVELOPMENT 256
17.20 PLEXBIO 257
17.20.1 COMPANY SNAPSHOT 257
17.20.2 PRODUCT PORTFOLIO 257
17.20.3 RECENT DEVELOPMENTS 257
17.21 QUEST DIAGNOSTICS INCORPORATED 258
17.21.1 COMPANY SNAPSHOT 258
17.21.2 REVENUE ANALYSIS 258
17.21.3 PRODUCT PORTFOLIO 259
17.21.4 RECENT DEVELOPMENTS 259
17.22 STERNMED GMBH 260
17.22.1 COMPANY SNAPSHOT 260
17.22.2 PRODUCT PORTFOLIO 260
17.22.3 RECENT DEVELOPMENTS 260
17.23 TIME MEDICAL HOLDING 261
17.23.1 COMPANY SNAPSHOT 261
17.23.2 PRODUCT PORTFOLIO 261
17.23.3 RECENT DEVELOPMENT 261
18 QUESTIONNAIRE 262
19 RELATED REPORTS 266
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security